95 filings
Page 5 of 5
6-K
8ak8mnk0vnhfstpqly0
26 Jun 19
Current report (foreign)
5:16pm
6-K
iqsh5s1e66fyc7caq3he
25 Jun 19
ERYTECH Announces Opening of Operations at its New
12:00am
6-K
wr1atfi zu
7 Jun 19
Reports Financial Results for First Quarter 2019
4:51pm
6-K
cbhkgvx1jcp39
4 Jan 19
Unaudited Interim Condensed Consolidated Statements of Financial Position
8:51am
6-K
4wodn598iuw4 dgz1
17 Jul 18
ERYTECH Pharma Reports Voting Results from
4:56pm
6-K
nmer16 eje
25 Jun 18
Current report (foreign)
6:06am
6-K
c7gf1v ozj
15 Jun 18
ERYTECH to Present Preclinical and Clinical Data on Use
12:00am
6-K
fz0 vlwjpuhfjsw1b7
7 Jun 18
Current report (foreign)
7:03am
6-K
lms7s
4 Jun 18
ERYTECH to Present Pharmacodynamic Data from
12:00am
6-K
pyv7qrixg 34pf
14 May 18
Appointment of Alex Dusek as VP of Commercial Strategy
4:57pm
6-K
e3dwtj hl
12 Apr 18
ERYTECH to Present Results from Phase I Trial of eryaspase in ALL and NewPre-clinical Data at AACR 2018
12:00am
6-K
28jnxo tktaocza6r
12 Mar 18
Reports Financial Results for Full Year 2017
12:00am
6-K
envpq
13 Feb 18
Erytech Pharma 6-K
12:00am
6-K
6bsw3su u7slb6k6l
8 Dec 17
ERYTECH ReportsTop-line Results of Phase 2b Study of Eryaspase for the Treatment of AML
12:00am
6-K
d17cl
7 Dec 17
Unaudited Interim Condensed Consolidated Statements of Financial Position
12:00am